Prospective Investigation of The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Venous Outflow Circuit Obstruction In Hemodialysis Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 6
- 主要终点
- Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days
研究概览
简要总结
This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm or thoracic central veins of subjects who receive chronic dialysis treatment for end stage renal disease.
详细描述
The study will consist of a screening period in which subject eligibility will be determined. Approximately 50 subjects meeting the study entry criteria will be enrolled. Placement of the WRAPSODY stent graft will follow the procedure. Post study procedure subjects will have planned follow-up visits at 30 days, 3, 6 and 12months, and additional visits as referred by the subject's dialysis facility.
The primary study safety endpoint will be the proportion of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death. Subjects will continue to be followed up to 12 months for supplementary information.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has signed informed consent
- •Subject is ≥ 21 years of age
- •Subject is undergoing chronic hemodialysis or other forms of renal replacement therapy including transplantation and has one of the following being used: a. AV graft placed in the arm ≥30 days prior OR b. Mature fistula in the arm with at least one successful dialysis session completed
- •Angiographic evidence of stenosis
- •The target lesion has ≥ 50% stenosis
- •Subject has clinical or hemodynamic evidence of a venous outflow stenosis or obstruction
- •Full expansion of an appropriately sized standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment
排除标准
- •Subject has undergone an intervention (surgical or percutaneous) of the AVF/AVG <30 days from the date of the initial study procedure
- •Subject has had a previous stent or stent graft placed in the venous outflow circuit ≤30 days from the date of the initial study procedure
- •Active hemodialysis access is not in the arm
- •A pseudoaneurysm is present within the target lesion
- •Target lesion is in SVC, IJV, under the clavicle, across the elbow, in the needling segment of AVF or AVG anastomosis, located within a stent
- •Lesions, other than the target lesion, in the venous outflow circuit with >30% stenosis
- •Known or suspected infection of the hemodialysis access site and/or septicemia
- •Permanent pacemaker or automated implantable cardioverter defibrillator (AICD) on the side with the target lesion
- •Current central venous catheter for dialysis access
- •Uncorrectable coagulation disorders
- •Hypersensitivity to nickel titanium alloy
- •The subject is enrolled in another investigational study
- •The subject is unable or unwilling to comply with the protocol requirements
- •Life expectancy is ≤ 12 months
- •Subject cannot receive heparin or equivalent anticoagulant
- •Allergy to radiographic contrast material which cannot be adequately premedicated
- •Subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant
- •Subject's access is anticipated to be abandoned within 3 months
- •Subject has a thoracic central vein obstruction that would lead to stent graft placement across the internal jugular vein
- •Subject's hemodialysis access is thrombosed
- •Active malignancy other than non-melanomatous skin cancer
- •Any other condition deemed exclusionary in the opinion of the investigator
结局指标
主要结局
Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days
时间窗: 30 days
The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death
Number of Participants With Target Lesion Primary Patency at 30 Days
时间窗: 30 days
The total number of subjects with Target Lesion Primary Patency at 30 days
次要结局
- Number of Participants With Target Lesion Primary Patency at 3 Months(3 months)
- Number of Participants With Target Lesion Primary Patency at 6 Months(6 months)
- Number of Participants With Target Lesion Primary Patency at 12 Months(12 months)
- Number of Participants With Assisted Target Lesion Primary Patency at 30 Days(30 days)
- Number of Participants With Assisted Target Lesion Primary Patency at 3 Months(3 months)
- Number of Participants With Assisted Target Lesion Primary Patency at 6 Months(6 months)
- Number of Participants With Assisted Target Lesion Primary Patency at 12 Months(12 months)
- Number of Participants With Access Circuit Primary Patency at 30 Days(30 days)
- Number of Participants With Access Circuit Primary Patency at 3 Months(3 months)
- Number of Participants With Access Circuit Primary Patency at 6 Months(6 months)
- Number of Participants With Access Circuit Primary Patency at 12 Months(12 months)
- Number of Participants With Assisted Access Circuit Primary Patency at 30 Days(30 days)
- Number of Participants With Assisted Access Circuit Primary Patency at 3 Months(3 months)
- Number of Participants With Assisted Access Circuit Primary Patency at 6 Months(6 months)
- Number of Participants With Assisted Access Circuit Primary Patency at 12 Months(12 months)
- Number of Participants With Clinical Success(30 days)
- Number of Participants With Anatomic Success(Immediately following the study procedure)
- Number of Participants With Procedural Success(30 days)